Global Peptide Therapeutics Market 2023-2028: Advancements in Peptide Therapeutics Transform Medical Landscape with Targeted Treatments

Dublin, Aug. 30, 2023 (GLOBE NEWSWIRE) -- The "Global Peptide Therapeutics Market (2023-2028) by Synthesis Technology, Drug Class, Route of Administration, API Type, Application, End User, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to's offering.

The global Peptide Therapeutics market is poised for substantial growth, with an estimated value of USD 32.84 billion in 2023, projected to reach USD 53.04 billion by 2028, exhibiting an impressive Compound Annual Growth Rate (CAGR) of 10.06% during the forecast period.

Market Overview

Peptides, short chains of amino acids, have shown great potential in targeting specific biological processes within the body. Their ability to mimic natural proteins and influence biological functions makes them a promising avenue for therapeutic development. Peptide-based treatments offer targeted and efficient alternatives to traditional medications, often with fewer side effects.

Market Dynamics

The global rise in cancer, cardiovascular diseases, and metabolic disorders has driven the demand for effective and targeted therapies. Peptide therapies, with their ability to precisely target disease-related processes, are emerging as potential solutions. These therapies are gaining traction as viable options for patients seeking more effective and safer treatment options for these serious conditions.

Advancements in biotechnology and drug development have paved the way for new platforms to create next-generation protein and peptide therapies. These platforms enable the design, manufacturing, and delivery of more stable, potent, and selective peptide medicines. As pharmaceutical companies invest in these advanced techniques, the peptide therapeutics market is experiencing rapid expansion, attracting both research and commercial investments.

Continued innovation in biotechnology and peptide research has unlocked new avenues for drug development. Ongoing research in new peptides and improved synthesis processes, coupled with substantial research and development investments, is resulting in more stable, efficient, and tailored treatments. The continuous technological advancement and financial commitment in the peptide sector offer significant potential for the development of advanced pharmaceuticals to address unmet medical needs.

Market Segmentations

The market is segmented based on Synthesis Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Calcitonins, Glucagon & Analogs, Insulins, Luteinizing Hormone-Releasing Hormone, Somatostatins, Vasopressin), Route of Administration (Parenteral, Oral), API Type (CMO, In-house), Application (Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, Other Applications), and End User (Hospitals, Pharmaceutical Industries, Research Laboratories).

Among these segments, Solid Phase Synthesis is a dominant method due to its versatility and scalability. Insulins hold a significant market share, driven by their critical role in diabetes treatment. The parenteral route of administration is preferred for peptide therapies due to their sensitivity to digestive breakdown. Pharmaceutical industries play a crucial role as end users, driving the creation and distribution of peptide therapies.

Recent Developments

Recent developments include the launch of Peptide Therapy Gel by CHOSEN by Dermatology for intense skin repair and rejuvenation, as well as Evonik's introduction of a next-generation peptide for biopharma applications.

Companies Mentioned

  • AmbioPharm Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bachem Holding Ag
  • Bristol-Myers Squibb Company
  • Corden Pharma GmbH
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ag
  • Hemmo Pharmaceuticals Pvt. Ltd.
  • Ipsen SA
  • Merck & Co., Inc.
  • Novartis International Ag
  • Novo Nordisk AS
  • Pfizer Inc.
  • PolyPeptide Group
  • Sanofi SA
  • Takeda Pharmaceutical Co.Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma AS


The global Peptide Therapeutics market is poised for remarkable growth, driven by increasing prevalence of diseases, advancements in biotechnology, and ongoing research and innovation in peptide development. While challenges exist, including stability issues of naturally occurring peptides and stringent safety regulations, opportunities abound for the industry to deliver targeted and efficient therapies to meet the evolving needs of patients.

Key Attributes:

Report AttributeDetails
No. of Pages128
Forecast Period2023 - 2028
Estimated Market Value (USD) in 2023$32.84 Billion
Forecasted Market Value (USD) by 2028$53.04 Billion
Compound Annual Growth Rate10.0%
Regions CoveredGlobal

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Global Peptide Therapeutics Market

Contact Data